Sri Nuvvula

Sri Nuvvula

Auto-generated profile, based on publicly available information

Sri Nuvvula

Cardiovascular Institute Northwell Health, North Shore University Hospital New Hyde Park New York USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2026 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
MAMichael Alston
Michael Alston
SNSri Nuvvula
Sri Nuvvula
CPCatherine Pham
Catherine Pham
JTJulie Thomas
Julie Thomas
JGJames K. Gabriels
James K. Gabriels
LELaurence M. Epstein
Laurence M. Epstein

19 September 2026 in JACC: Case Reports
Verified
Journal Article
Open access
SNSri Nuvvula
Sri Nuvvula
MMMaryyam Mian
Maryyam Mian
ASAvneet Singh
Avneet Singh
JDJoseph Diamond
Joseph Diamond

29 October 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
SNSri Nuvvula
Sri Nuvvula
ACAdrian Chen
Adrian Chen
Amgad N. MakaryusAmgad N. Makaryus
Amgad N. Makaryus
Cardiac rehabilitation (CR) has been categorized as a class Ia recommendation for secondary prevention after major cardiac interventions or in patients with certain cardiac comorbidities. The benefits of CR have been established and range from reducing readmissions to improving quality of life. Given the increasing amount of literature on CR over the past few years and the evolution of this field, there is a need to synthesize these data. Thus, this review aims to combine the latest research findings to provide a comprehensive review of CR literature. We discuss the components needed to create a successful CR program, including individualized training plans, routine clinical assessments, exercise supervision, and nutritional assessments. Overall rates of CR utilization remain low. Therefore, we explore potential reasons for this underutilization observed in the literature, including CR deserts, under-referral, and the lack of education on benefits, time, and transportation. Moreover, we discuss solutions for underutilization that have been analyzed in the literature, including motivational interviewing, gender-specific regimens, transportation assistance, and automatic referrals. Realizing the underutilization of CR, we also assess virtual CR (VCR) and variations in various regimens within the programs. We compare exercise and body metrics, patient outcomes, feasibility, and patient preferences between VCR and traditional CR published in the literature. VCR does not appear to be inferior to conventional CR in many metrics, although more research is needed to compare the two modalities. We recommend that providers explain the outcomes of the two modalities and allow patients to choose the regimen that works best for them. We discuss how VCR may be better suited to patient populations with specific barriers to care. We also discuss the ongoing current CR trials, many of which are focused on solutions to underutilization. Lastly, we further discuss the remaining gaps in the CR literature and areas where future research could be beneficial, such as establishing large-scale VCR studies and studies focused on expanding CR indications.

5 January 2026 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
SNSri Nuvvula
Sri Nuvvula
RRRahul Rege
Rahul Rege
SSSarah Siemers
Sarah Siemers
JDJennifer Drummond
Jennifer Drummond
BHBenjamin J. Hirsh
Benjamin J. Hirsh
NSNeil D. Shah
Neil D. Shah
Virtual cardiac rehabilitation (VCR) offers a potential strategy to expand access to cardiac rehabilitation and address participation barriers, including transportation, work obligations, and limited program availability. This retrospective cohort study compared quality-of-life, functional capacity, and other clinical outcomes between patients enrolled in VCR and traditional cardiac rehabilitation (TCR) at a single academic center between June 2022 and August 2024. Outcomes of interest included changes in Dartmouth COOP quality-of-life scores, metabolic equivalents (METs), Patient Health Questionnaire-9 (PHQ-9), Rate Your Plate dietary scores, body mass index (BMI), and systolic and diastolic blood pressure. A total of 171 patients (40 VCR, 131 TCR) were included. VCR participants demonstrated greater improvement in Dartmouth COOP scores (–5.13 ± 4.65vs –3.20 ± 4.34; p < 0.05), whereas TCR participants had comparable improvements in METs (1.93 ± 1.19 vs 0.92 ± 0.85; p = 0.11). No significant differences were observed in PHQ-9, Rate Your Plate scores, BMI, or blood pressure. In exploratory subgroup analyses, female participants in VCR had greater quality-of-life improvement (–6.18 ± 4.85 vs –2.86 ± 3.85; p < 0.05), while TCR participants had greater MET improvement among those with ≥5 mmHg diastolic blood pressure reduction. VCR was associated with quality-of-life improvements comparable to TCR and may offer potential benefits for women, while TCR produced larger functional capacity gains in subgroup analyses. These findings are hypothesis-generating, reflect a single-center predominantly homogenous population, and require confirmation in prospective, randomized studies.

30 September 2025
Verified
Preprint
Open access
SNSri Nuvvula
Sri Nuvvula
GSGidon Salamatbad
Gidon Salamatbad
SSSamer Saouma
Samer Saouma
RSRina Shah
Rina Shah
PAPhilippe Akhrass
Philippe Akhrass
VPValay Parikh
Valay Parikh
Introduction Pulse Field Ablation (PFA) has proven its efficacy and safety profile through multiple studies for atrial fibrillation. However, there is limited insight into the post-market outcomes given the recency of the approvals. Methods Our objective is to characterize the major device and patient complications of PFA in the United States outside the controlled setting of clinical trials using the Manufacturer and User Facility Device Experience (MAUDE) database and review complications shown in published major clinical studies. We used the Food and Drug Administration (FDA) MAUDE Database to assess device and patient complications from PFA technologies. We also discussed all the trials in which PFA was performed and searched through multiple databases. Results From the MAUDE database, there were 649 events reported involving entrapment of the device. Reported structural cardiac events included 295 pericardial effusion events and 150 cardiac tamponade events. After FDA approval, the number of FARAPULSE events was 88 death events and 1,180 injury events. After FDA approval, the number of PulseSelect events was 9 deaths and 220 injury events. There were 50 published studies that described the outcomes of PFA for atrial fibrillation that met our selection criteria. The most common complications were pericardial tamponade (0.00-5.00%), coronary spasm (0.00-5.00%) and stroke (0.00-4.35%). Conclusion The risk of serious adverse events that we reported necessitates continued refinements of device design and operator technique to improve patient outcomes. Establishing a rigorous registry in the early stage of adoption of PFA technology is strongly warranted to identify complications accurately.